Quarterly report pursuant to Section 13 or 15(d)

COLLABORATIONS, LICENSE AGREEMENTS AND COMMITMENTS (Narrative) (Details)

v3.19.1
COLLABORATIONS, LICENSE AGREEMENTS AND COMMITMENTS (Narrative) (Details)
€ in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Sep. 30, 2019
shares
Apr. 30, 2019
USD ($)
Feb. 28, 2019
USD ($)
Jan. 16, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
shares
Mar. 31, 2019
EUR (€)
shares
Feb. 28, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Feb. 28, 2019
CAD ($)
Dec. 31, 2018
EUR (€)
Research and development expense         $ 1,431,000 $ 5,150,000   $ 766,000        
Consolidation of CDMO Entities and Strategic Funding [Member]                        
Consolidation agreement, initial cash payment           11,800,000            
Consolidation agreement, initial cash payment, amount used to reimburse investors           1,500,000            
Consolidation agreement, initial cash payment, net payment           10,300,000            
Consolidation agreement, follow up payments       $ 6,600,000         $ 6,600,000 $ 13,200,000    
Image Securities Ltd. [Member]                        
Payments to Acquire Interest in Joint Venture     $ 1,000,000                  
Loans Receivable, Net           2,000,000            
Consulting services to joint venture     1,000,000                  
Hemogenyx Pharmaceuticals PLC. [Member]                        
Loans Receivable, Net         250,000       250,000      
Immugenyx, LLC [Member]                        
Loans Receivable, Net         250,000       250,000      
Theracell Advanced Biotechnology [Member]                        
Joint venture agreement, investment per party           10,000,000            
Joint venture agreement, investments in the form of in-kind contributions           5,000,000            
Joint venture agreement, investment, convertible loan           10,000,000            
Joint venture agreement, minimum pre-money valuation of investment           $ 20,000,000            
Royalty of net sales, percentage           15.00% 15.00%          
Interest in joint venture           50.00%            
Noncontrolling interest in joint venture           50.00%            
First Choice International Company, Inc. [Member]                        
Joint venture agreement, investment per party           $ 5,000,000            
Royalty of net sales, percentage           15.00% 15.00%          
Interest in joint venture           50.00%            
Noncontrolling interest in joint venture           50.00%            
Joint venture agreement, payments for compensation of work already completed   $ 50,000       $ 50,000            
Joint venture agreement, shares issued for compensation of work already completed | shares 150,000         375,000 375,000          
Research and development expense           $ 2.6            
Cure Therapeutics Collaboration Agreement [Member]                        
Research and development expense         331,000 166,000            
Subcontracted development and contract manufacturing activities         82,000 208,000            
Belgian subsidiary [Member]                        
Grant approval, maximum financial support         $ 350,000       $ 350,000     € 317
Proceeds from advance payment of grant           $ 90,000 € 80          
Israeli subsidiary and a Canadian partner [Member]                        
Grant approval, maximum financial support     $ 75,000               $ 100